Hanahan pioneered the genetic engineering of transgenic mouse models to study human cancer. In collaboration with Judah Folkman, he discovered the “angiogenic switch,” a process that enables new blood vessel formation and facilitates tumor progression towards malignancy. Dr. Hanahan spent twenty-one years at the University of California San Francisco, in the
UCSF Diabetes Center prior to EPFL in 2009. During that time (2000), Hanahan co-authored a seminal paper with
Robert Weinberg entitled
The Hallmarks of Cancer, which proposed a conceptual framework for understanding the complexity of cancer development. This was followed by updated reviews in 2011 and 2022. He was instrumental in founding the Swiss Cancer Center Leman (SCCL), the first comprehensive cancer center in Switzerland. Hanahan also played a key role in developing the Agora Translational Cancer Research Center, a collaborative facility designed to advance cancer research and therapy. ==Awards and honors==